Press Releases CNS Pharmaceuticals, Inc.

Equities

CNSP

US18978H3003

Real-time Estimate Cboe BZX Other stock markets 12:00:49 2024-06-26 EDT			5-day change	1st Jan Change
1.8 ^USD	-36.62%		-18.77%	-97.28%

03:28pm	Wall Street Set to Open Marginally Lower Ahead of New Home Sales, GDP Figures	MT
06-14	CNS Pharmaceuticals, Inc. announced that it expects to receive $1.3725 million in funding	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement	06-17	AQ
CNS Pharmaceuticals to Present at Alliance Global Partner's 2024 Healthcare Company Showcase	05-21	AQ
CNS Pharmaceuticals Reports First Quarter 2024 Financial Results	05-17	AQ
CNS Pharmaceuticals to Present at the LSX World Congress 2024	04-24	AQ
CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break, the CNSP Opportunity	04-23	AQ
CNS Pharmaceuticals to Present at Two Investor Conferences in April	04-02	AQ
CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering	01-30	AQ
Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors	01-19	AQ
CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme	01-18	AQ
CNS Pharmaceuticals : Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin - Form 8-K	12-18	PU
How CNS Pharmaceuticals Is Taking a Different Approach to Find a Treatment for Glioblastoma, a Cancer with a Poor Prognosis and No Cure	12-07	AQ
CNS Pharmaceuticals to Release Interim Data by the End of the Year for Potential Glioblastoma Drug Candidate	11-17	AQ
CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study before Year End	11-16	AQ
CNS Pharmaceuticals : Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End - Form 8-K	11-15	PU
CNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO Conference	23-10-20	AQ
CNS Pharmaceuticals : Regulation FD Disclosure - Form 8-K	23-10-18	PU
Glioblastoma Is the Most Aggressive Type of Brain Cancer, With No Cure - CNS Pharmaceuticals Innovative Approach to Treatment Could Offer Hope	23-10-17	AQ
CNS Pharmaceuticals Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date	23-10-12	AQ
CNS Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference	23-09-06	AQ
CNS Pharmaceuticals Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM after Failure of Standard First Line Therapy	23-08-15	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases CNS Pharmaceuticals, Inc.

Equities

CNSP

US18978H3003

Press Releases

Filters